Video

Dr. Richards on Urinary Tract Infections Associated With Worse Bladder Cancer Outcomes

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses a retrospective analysis of the association between urinary tract infections (UTI) and worse outcomes in patients with bladder cancer from a Medicare database analysis.

A recent study used Surveillance, Epidemiology, and End Results (SEER) Medicare data to examine a cohort of patients with bladder cancer. Researchers analyzed the symptoms patients presented with and if it was a hematuria or UTI claim, as well as the time frame from symptom presentation to diagnosis.

Researchers then went forward to examine the outcomes of these patients and if they varied, based on time of diagnosis and presented symptoms, Richards explains.

Data showed that women who presented with a UTI claim had worse pathology and survival outcomes compared to women with hematuria. There was a similar association with men enrolled in the study; however, the association was greater in women.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center